Dr. Michael Devous

Michael D. Devous, Sr., Ph.D., FSNMMI, is President of MDD Enterprises LLC, a medical and scientific consulting company. He also currently serves as Chairman of the Board for the Alzheimer’s Association New Mexico Chapter. He was Vice President of Imaging at Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company through May of 2021. His responsibilities included serving on the Executive Committee, directing the Imaging Sciences Department, and designing, executing, analyzing, and interpreting clinical trials.

He also served on clinical trial design, analysis, and interpretation teams for therapeutics developed by Eli Lilly and Company with a focus on imaging and non-imaging biomarkers and their role in therapeutic clinical trials for neurodegenerative disorders. He was also previously Professor of Radiology, Neurology, and Bioengineering, Director of the Alzheimer’s Disease Center Neuroimaging Core, Co-Principal Investigator of the North Texas Traumatic Brain Injury Model System, and Associate Director of the Nuclear Medicine Center at the University of Texas Southwestern Medical Center, Dallas, Texas. He remains an Adjunct Professor of Neurology at UT Southwestern and of Behavioral and Brain Sciences at the University of Texas at Dallas.

He has authored more than 200 peer- reviewed articles, 380 abstracts, and 30 books or book chapters. Dr. Devous is past president of the Society of Nuclear Medicine, the Education and Research Foundation, and the Brain Imaging Council. He is a former chair of the Food and Drug Administration Medical Imaging Drugs Advisory Committee. His research focuses clinical trials of diagnostics and therapeutics (primarily in neurodegenerative disorders) and on advancing the understanding of the pathobiology of neurologic and psychiatric disorders, and normal brain function, through molecular, functional, and structural neuroimaging techniques.